Michael Sy, MD
Neurology · Irvine, CANPI 1376835629
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (47.8%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. AstraZeneca accounts for 62.5% of it on its own, with 12 other manufacturers making up the rest. 2025 is the largest year on record at $69,130, more than ten times the $39 reported in 2019. Among neurology clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 172 payments — averaging $529.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$57K
- Genentech USA, Inc.$14K
- Amgen$6K
- UCB, Inc.$4K
- Novartis$3K
- TG Therapeutics, Inc.$2K
- plus $4K from 7 others
Across 155 payments — averaging $10,910 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$943K
- Novartis$212K
- Sanofi$212K
- TG Therapeutics, Inc.$205K
- E.r. Squibb & Sons, L.L.C.$45K
- Bristol Myers Squibb$37K
- plus $37K from 3 others
What the payments were for
- Consulting fees$37,36841%
- Speaking & faculty fees$43,46048%
- Travel & lodging$5,1346%
- Food & beverage$4,9205%
- Education$1190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 57 | $56,846 |
| Genentech USA, Inc. | 17 | $13,795 |
| Amgen(2 entities) | 17 | $6,066 |
| UCB, Inc. | 2 | $4,474 |
| Novartis | 31 | $3,412 |
| TG Therapeutics, Inc. | 13 | $2,154 |
| Genentech, Inc. | 7 | $1,761 |
| E.r. Squibb & Sons, L.L.C. | 1 | $1,280 |
| Biogen | 8 | $699 |
| Vanda Pharmaceuticals Inc. | 10 | $209 |
| Bristol Myers Squibb | 5 | $144 |
| Sanofi | 3 | $143 |
| Therapeuticsmd, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ULTOMIRIS$41,653
- UPLIZNA$5,589
- OCREVUS$5,353
- EVUSHELD$3,700
- KESIMPTA$2,700
- BRIUMVI$1,807
- Enspryng$1,260
- TYSABRI$450
- Ocrevus Zunovo$116
- FLUMIST QUADRIVALENT$107
How this compares
$91,002 in reported general payments places this provider in the 90th percentile of 1,996 neurology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SolirisEculizumab | 58 | $1,643,678 |
| UltomirisRavulizumab-Cwvz | 12 | $782,850 |
| EnspryngSatralizumab-Mwge | 43 | $736,556 |
| Kesimpta PenOfatumumab | 56 | $460,190 |
| CopaxoneGlatiramer Acetate | 53 | $383,657 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 18 | $225,262 |
| TecfideraDimethyl Fumarate | 15 | $131,336 |
| Glatiramer Acetate | 47 | $84,076 |
| Dalfampridine ErDalfampridine | 26 | $19,013 |
| Aimovig AutoinjectorErenumab-Aooe | 14 | $13,226 |
| Baclofen | 103 | $4,072 |
| Dimethyl Fumarate | 13 | $2,967 |
| Lacosamide | 13 | $2,268 |
| Gabapentin | 54 | $1,172 |
| Duloxetine Hcl | 20 | $1,141 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaSoliris, Ultomiris | $56,846 | $2,426,52870 claims |
| Genentech USA, Inc.Enspryng | $13,795 | $736,55643 claims |
| BiogenTecfidera | $699 | $131,33615 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,996 neurology providers in California.
Other neurology in Irvine
- Sandeep ThakkarIrvine$2M
- Andrew BlumenfeldCarlsbad$4.9M
- Khashayar DashtipourLoma Linda$3.3M
- Regina BerkovichWest Hollywood$3M
- Daniel BandariNewport Beach$2.6M
- Perry ShiehLos Angeles$2.4M
- David LiebeskindLos Angeles$1.9M
- Jack SchimCarlsbad$1.7M
- Parshaw DorrizMission Viejo$1.5M
- Benjamin FrishbergCarlsbad$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.